RATIONALE: Alprazolam extended-release (XR) is approved for the treatment of panic disorder. This sustained formulation is absorbed in a delayed manner and is therefore expected to produce fewer and less severe side effects than its immediate release equivalent (alprazolam IR). The effect of alprazolam XR on potentially dangerous daily activities, such as driving a car, is expected to be less as compared to alprazolam IR. OBJECTIVES: The present study was designed to compare the effects of alprazolam XR (1 mg) and alprazolam IR (1 mg) on actual driving ability and cognitive function. METHOD:Eighteen healthy volunteers (aged 20-45 years) participated in a double-blind, placebo-controlled, three-way crossover study. At 4 h post-dose, subjects performed a standardized driving test on a primary highway in normal traffic. Cognitive and psychomotor tests were assessed 1, 2.5, and 5.5 h post-dose. Memory functioning was measured only 1 h after administration. RESULTS: Both formulations severely impaired driving performance between 4 and 5 h after administration. The magnitude of impairment in the driving test observed with alprazolam XR was about half that observed with alprazolam IR. Laboratory test results were in line with the driving data. CONCLUSIONS: The acute impairing effects of alprazolam XR 1 mg on driving and psychomotor functions were generally less, as compared to its immediate-release equivalent, but still of sufficient magnitude to increase the risk of becoming involved in traffic accidents.
RCT Entities:
RATIONALE: Alprazolam extended-release (XR) is approved for the treatment of panic disorder. This sustained formulation is absorbed in a delayed manner and is therefore expected to produce fewer and less severe side effects than its immediate release equivalent (alprazolam IR). The effect of alprazolam XR on potentially dangerous daily activities, such as driving a car, is expected to be less as compared to alprazolam IR. OBJECTIVES: The present study was designed to compare the effects of alprazolam XR (1 mg) and alprazolam IR (1 mg) on actual driving ability and cognitive function. METHOD: Eighteen healthy volunteers (aged 20-45 years) participated in a double-blind, placebo-controlled, three-way crossover study. At 4 h post-dose, subjects performed a standardized driving test on a primary highway in normal traffic. Cognitive and psychomotor tests were assessed 1, 2.5, and 5.5 h post-dose. Memory functioning was measured only 1 h after administration. RESULTS: Both formulations severely impaired driving performance between 4 and 5 h after administration. The magnitude of impairment in the driving test observed with alprazolam XR was about half that observed with alprazolam IR. Laboratory test results were in line with the driving data. CONCLUSIONS: The acute impairing effects of alprazolam XR 1 mg on driving and psychomotor functions were generally less, as compared to its immediate-release equivalent, but still of sufficient magnitude to increase the risk of becoming involved in traffic accidents.
Authors: R J Bertz; P D Kroboth; F J Kroboth; I J Reynolds; F Salek; C E Wright; R B Smith Journal: J Pharmacol Exp Ther Date: 1997-06 Impact factor: 4.030
Authors: Hélder Fernandes; Vânia Batalha; Ellen Braksator; Simon Hebeisen; Maria João Bonifácio; Maria Augusta Vieira-Coelho; Patrício Soares-da-Silva Journal: Pharmacol Rep Date: 2022-09-12 Impact factor: 3.919
Authors: Jeffrey R Brubacher; Herbert Chan; Walter Martz; William Schreiber; Mark Asbridge; Jeffrey Eppler; Adam Lund; Scott Macdonald; Olaf Drummer; Roy Purssell; Gary Andolfatto; Robert Mann; Rollin Brant Journal: BMJ Open Date: 2016-03-10 Impact factor: 2.692
Authors: Eric M Pearlman; Darren Wilbraham; Ellen B Dennehy; Paul H Berg; Max Tsai; Erin G Doty; Gary G Kay Journal: Hum Psychopharmacol Date: 2020-05-25 Impact factor: 1.672
Authors: Bradly T Stone; Kelly A Correa; Timothy L Brown; Andrew L Spurgin; Maja Stikic; Robin R Johnson; Chris Berka Journal: Front Psychol Date: 2015-11-26
Authors: Zahid Sadek Chowdhury; Mohammed Monzur Morshed; Mohammad Shahriar; Mohiuddin Ahmed Bhuiyan; Sardar Mohd Ashraful Islam; Muhammad Shahdaat Bin Sayeed Journal: Behav Neurol Date: 2016-07-04 Impact factor: 3.342